



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHOI *et al.*

Appl. No.: 10/580,132

Int'l Filing Date: January 6, 2006

For: **A Dicarboxylic Acid Salt of
Sibutramine**

Confirmation No.: 9220

Art Unit: 1621

Examiner: Davis, Brian J.

Atty. Docket: 2511.0030000/JUK/DLL

Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1-FP4** and **NPL1-NPL6** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of the U.S. patent and published patent applications, documents **US1-US4**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

U.S. Non-Provisional Application No. 10/580,136, inventors LIM *et al.*, 35 U.S.C. § 371 date of March 2, 2007, which is the U.S. National Phase of International Application No. PCT/KR06/00073, filed on January 6, 2006; pending and submitted herewith as document **US2**; and

01/07/2008 SZEWDIE1 00000066 10580132

01 FC:1806

180.00 0P

U.S. Non-Provisional Application No. 10/580,135, inventors LIM *et al.*, 35 U.S.C. § 371 date of March 2, 2007, which is the U.S. National Phase of International Application No. PCT/KR06/00072, filed on January 6, 2006; pending and submitted herewith as document US3.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to the application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Audith U. Lim Reg. No. 40,679

for Danielle L. Letting
Agent for Applicants
Registration No. 56,971

Date: January 4, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

763783_1.DOC